Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Gilead | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Gilead

Sovaldi sales drive record growth

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Gilead

4Q Revenues: $7.3 billion (+110%)

4Q Earnings: $3.5 billion (earnings were $791 million 4Q13)

FY Revenues: $24.9 billion (+250%)

FY Earnings: $12.1 billion (earnings were $3.1 billion FY13)

Comments: Antiviral product sales were $6.7 billion in the quarter compared to $2.6 billion in 4Q13, driven by Sovaldi sales, which launched in December 2013 in the U.S. and in January 2014 in Europe, and Harvoni, which launched in the U.S. in October 2014. Letairis, Ranexaand AmBisome sales totaled $496 million in the quarter, up 23%. In the quarter, product sales in the U.S. were $5.5 billion compared to $1.9 billion in 4Q13, and in Europe, product sales were $1.4 billion compared to $871 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters